Evidence map›Paper›PMID 30567199›Full record

ArticleBMJ case reports2018

Use of platelet and erythroid growth factors during induction chemotherapy for acute lymphoblastic leukaemia in a Jehovah's Witness.

Nivedita Arora, Arjun Gupta, Hsiao C Li, Navid Sadeghi

Open access · greenAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ case reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Nivedita AroraDepartment of Internal Medicine, University of Texas Southwestern, Dallas, Texas, USA.ORCID http://orcid.org/0000-0002-8762-577X
Arjun GuptaDepartment of Internal Medicine, University of Texas Southwestern, Dallas, Texas, USA.
Hsiao C LiDivision of Hematology and Oncology, Department of Internal Medicine, University of Texas Southwestern, Dallas, Texas, USA.
Navid SadeghiDivision of Hematology and Oncology, Department of Internal Medicine, University of Texas Southwestern, Dallas, Texas, USA.
Parkland Health & Hospital System · USThe University of Texas Southwestern Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We present a 21-year-old woman diagnosed with Philadelphia (Ph) chromosome-like CD20 positive B-cell acute lymphoblastic leukaemia (ALL). She was a Jehovah's Witness (JW) and declined all blood product transfusion support. She was initiated on the CALGB 10403 chemotherapy protocol for her ALL. She received darbepoetin alfa and romiplostim as supportive therapies for her disease/chemotherapy-associated anaemia and thrombocytopaenia. A complete remission was achieved with negative minimal residual disease and she remains in remission 18 months after diagnosis. This case report describes the successful treatment of an adult JW with Ph-like CD20 +B cell ALL, in the absence of blood product transfusions, using growth factor support.

Indexed as

Jehovah's WitnessesAntineoplastic Combined Chemotherapy ProtocolsDarbepoetin alfaFemaleHematinicsHumansInduction ChemotherapyPrecursor Cell Lymphoblastic Leukemia-LymphomaReceptors, FcReceptors, ThrombopoietinRecombinant Fusion ProteinsRemission InductionThrombopoietinTreatment RefusalYoung AdultDarbepoetin alfaHematinicsReceptors, FcReceptors, ThrombopoietinRecombinant Fusion ProteinsromiplostimThrombopoietinhealthcare improvement and patient safetymalignant and benign haematologytherapeutic indications

Identifiers

PMID30567199
PMCPMC6301473
OpenAlexW2904294740

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.